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Abstract 
Pancreatic cancer is the 3rd leading cause of cancer deaths in the United States. A combination regimen of 
folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) has an established efficacy in treating pancreatic ductal 
adenocarcinoma (PDAC) and is amenable to further drug combination, but the cellular signaling response to 
FOLFOX has not been determined. This study investigates the pathway involving c-Jun N-terminal Kinases 
(JNK), which unpublished data from our lab suggest is upregulated following FOLFOX treatment. We 
hypothesized that PDAC cells resist FOLFOX chemotherapy treatment in part by upregulating JNK, and that 
inhibiting this pathway could act synergistically with FOLFOX to treat PDAC. Cell lines derived from patient-
derived xenografts were treated with varying doses of either FOLFOX, an irreversible inhibitor of JNK, or both. 
Western blotting was then used to quantify the amounts of JNK and its downstream effector c-Jun to compare 
these expression levels between the different treatments. We found that JNK and c-Jun are upregulated in 
response to FOLFOX treatment. In addition, irreversible inhibition of JNK led to the decrease in c-Jun. 
Furthermore, an MTT cell viability assay was performed on the same treatment groups, which showed that 
FOLFOX and irreversible inhibition of JNK synergize to inhibit cell line growth. These findings suggest that 
targeting JNK using an irreversible inhibitor could act synergistically with FOLFOX to treat PDAC. 
 
Introduction 
 Cancer is the second leading cause of death in the United States, with pancreatic cancer being the 3rd 
leading cause of cancer deaths1. Pancreatic cancer has an overall 5-year survival rate of under 5%1. Late-stage 
diagnosis, frequent metastasis, and lack of effective targeted therapies are responsible for the increasing 
incidence and overall mortality of pancreatic cancer2. Surgery is the only potential cure, but only 15-20% of 
patients present with resectable tumors upon diagnosis3. Therefore, chemotherapy is used extensively as a first-
line therapy for patients with unresectable tumors, as well as adjuvant therapy for patients that undergo 
surgery3. 
        Chemotherapy combination regimens have been established as the standard of care in the treatment of 
pancreatic cancer, most of which are based on the drug gemcitabine or the combination of drugs known as 
FOLFOX3. Gemcitabine is well-studied in chemotherapy combination regimens and has been approved for 
treatment of pancreatic ductal adenocarcinoma (PDAC) since 19964. Unlike gemcitabine, few studies of 
signaling responses to FOLFOX have been performed, despite FOLFOX chemotherapy combination regimens 
having an established efficacy and FOLFOX being amenable to further drug combination5. 
 The FOLFOX chemotherapeutic is made up of folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX, 
2016). 5-Flourouracil (5-FU) prevents DNA replication via inhibition of thymidylate synthase (TS). Folinic acid 
is a vitamin that enhances effects of 5-FU by stabilizing the inhibitory 5-FU+TS complex. Oxaliplatin (OX) is a 
platinum-based agent that cross-links DNA, preventing replication & transcription6. 
 Studying the signaling responses to FOLFOX could inform the rational design of drug combination 
therapies with increased effectiveness, and lead to much-needed progress for pancreatic cancer treatment. 
Kinases are important signaling molecules that activate other kinases and downstream targets through 
phosphorylation7. Others have found that, in response to chemotherapy, cancer cells exhibit a signaling 
response through kinases to attempt to mitigate the effects of the chemotherapeutics. This is known as kinome 
reprogramming8. Preliminary (unpublished) data obtained in our lab using the multiplexed kinase inhibitor 
beads with mass spectrometry (MIB-MS) technique found that several kinases were upregulated in PDAC cells 
treated with FOLFOX. Central to these kinases were c-Jun N-terminal kinases (JNK). JNK signaling activation 
has been shown to promote the development of pancreatic cancer. Many of the other kinases found upregulated, 
such as tyrosine-protein kinase Met (Met), ephrin type-A receptor 2 (EPHA2), and other receptor tyrosine 
kinases (RTKs), are upstream in the signaling pathways involving JNK (Figure 1). JNK is directly activated by 
mitogen-activated protein kinases (MAPKs), specifically MKK4 and MKK7. JNK phosphorylates (activates) c-
Jun, a transcription factor that activates genes that induce cell growth, cell cycle progression, and angiogenesis9.   
 Based on JNK signaling’s known aberrant role in cancer and the preliminary MIB-MS data suggesting 
that JNK signaling is activated in response to FOLFOX, we hypothesized that PDAC cells resist FOLFOX 
chemotherapy treatment in part by upregulating JNK, and that inhibiting this pathway could act synergistically 
with FOLFOX to treat PDAC. The inhibitor we chose for our experiments was JNK-IN-8. The JNK-IN-8 
inhibits JNK from phosphorylating of c-Jun by covalently and irreversibly binding to JNK10 (Figure 1). JNK-










Materials & Methods 
Drugs, Antibodies, and Reagents 
JNK-IN-8 was from Selleck Chemicals (Houston, TX, USA). Folinic acid, 5-fluorouracil, and oxaliplatin were 
from UNC Hospitals Pharmacy (Chapel Hill, NC, USA). Antibodies against Phospho-JNK (Thr183/Tyr185), 
Phospho-c-Jun (Ser63), and c-Jun were from Cell Signaling (Beverly, MA, USA). The antibodies against 
JNK1+JNK2, p53, and p21 were from abcam (Cambridge, UK). The antibody against Ku80 was from GeneTex 
(Irvine, CA, USA). Invitrogen™ horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse 
secondary antibodies were from Thermo Scientific (Rockford, IL, USA). The Amersham™ ECL™ Prime 
Western Blotting Detection Reagent was from GE Healthcare (Chicago, IL, USA). Restore™ Western Blot 
Stripping Buffer was from Thermo Scientific (Rockford, IL, USA).  
 
Cell Culture and Mouse Treatments 
All cell culturing was performed by Matt Lipner (MD-PhD candidate). Capan-1, Capan-2, CFPAC-1, HPAF-2, 
HuPT3, MiaPaca-2, Panc-1, Panc-02.03, and SW1990 cell lines were obtained from the American Type Culture 
Collection (ATCC). The P0411 and P0422 patient-derived xenograft (PDX) cell lines were derived from tissue 
obtained from de-identified patients from the IRB-approved UNC Lineberger Comprehensive Cancer Center 
(LCCC) tissue procurement facility. Cells were cultured under conditions described in Lipner et al11. Mouse 
treatments were performed by the UNC LCCC Animal Models core facility. The specific drugs and doses are 
specified in the appropriate section of the results. Phosphate-buffered saline (PBS) was used as the vehicle for 
FOLFOX, while dimethyl sulfoxide (DMSO) was used as the vehicle for JNK-IN-8. 
 
Western Blots 
Western blotting was performed with the conditions described in Lipner et al., with some modifications11. After 
the indicated time of incubation with the treatment, cells were washed with PBS, harvested by scraping, and 
then lysed in 200 μL RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% 
Triton X, 1 mM NaF, and 0.25% Na deoxycholate and protease inhibitors. Protein extracts were 
electrophoresed on 12% SDS polyacrylamide gels and electrotransferred to polyvinylidene difluoride (PVDF) 
membranes. Membranes were blocked with 5% non-fat dried milk in Tris-buffered saline with 8 mmol Tween 
20 (TBST) for 1 hour. Membranes were incubated in primary antibodies at the dilution in 5% fetal bovine 
serum in TBST and length of time specified by the manufacturer. Membranes were incubated in secondary 
antibodies at 1:10000 dilutions in 5% non-fat dried milk in Tris-buffered saline with Tween 20 (TBST) for 1 
hour. Membranes were washed with TBST for 3, 10-minute periods between blocking, primary antibody 
incubations, secondary antibody incubations, and imaging. Immunoreactive bands were detected by 
chemiluminescence using the Amersham™ ECL™ Prime Western Blotting Detection Reagent. To re-probe the 
applicable blots for total JNK and total c-Jun, these membranes were stripped using the Restore™ Western Blot 
Stripping Buffer. Images were obtained using the Molecular Imager® ChemiDoc™ XRS+ instrument from 
Bio-Rad Laboratories, Inc. 
 
MTT Assay 
The MTT assay was performed and synergy was assessed by Matt Lipner (MD-PhD candidate) with the 
conditions described in Lipner et al.11. 
 
Results 
Primary antibody validations for anti-phosphorylated JNK (p-JNK), anti-JNK, anti-phosphorylated c-Jun (p-c-
Jun), and anti-c-Jun 
We first validated the primary antibodies to ensure their specificity. Cells were treated with short interfering (si) 
RNA that was non-specific (siNS) or specific to JNK or c-Jun. The siNS was used as a control. A lower (20 
nM) and a higher (50 nM) dose of siRNA targeting JNK or c-Jun was used to establish dose-dependent 
decreases in target protein expression that reinforce the specificity of each antibody. Ku80, an ubiquitously 
expressed nuclear protein that has functions relating to telomere stabilization, was used as a loading control12. 
We determined that the primary antibodies used to detect phosphorylated JNK (p-JNK) and total JNK were 
specific because a decrease in the expression level of p-JNK and total JNK were seen in the siJNK treated cells 
relative to the siNS treated cells (Figure 2A). The results for the cells treated with siRNA targeting c-Jun 
similarly show a decrease in the expression levels of phosphorylated c-Jun (p-c-Jun) and total c-Jun (Figure 




Figure 2. Primary antibody validations for anti-phosphorylated JNK (p-JNK), anti-JNK, anti-phosphorylated c-
Jun (p-c-Jun), and anti-c-Jun. Cells were treated with siNS, siJNK, or si c-Jun for 48 hours. The phosphorylated JNK 
and total JNK antibodies detect decreased p-JNK and total JNK relative to the siNS control (A). Likewise, the 
phosphorylated c-Jun and total c-Jun antibodies detect decreased p-c-Jun and total c-Jun relative to the siNS control (B). 
A colorimetric and a chemiluminescent image were merged to display the protein size ladder. 
Cell line panel examined for c-Jun expression levels 
We then examined the baseline expression levels of p-c-Jun and total c-Jun in a panel of cell lines commonly 
used in PDAC research from the ATCC as well as the PDX-derived cell lines established in our lab (Figure 3). 
Baseline c-Jun expression was considered to be more important than baseline JNK expression because the JNK-
IN-8 irreversible inhibitor being studied does not directly alter levels of JNK, but rather levels of its 
downstream effectors by inhibiting binding of JNK to its targets. The blot shows that the P0411 PDX cell line 
expresses p-c-Jun and total c-Jun at moderate baseline levels. For this reason, the P0411 cell line was used in all 
other experiments presented here, since a moderate expresser is likely the most representative.  
 
 
Figure 3. Cell line panel examined for c-Jun expression levels. Both PDX and ATCC cell lines were probed 








Phosphorylated JNK and c-Jun show increased expression levels 12 hours after FOLFOX treatment 
P0411 cells were treated with with the PBS vehicle as the control, or with IC25 or IC50 doses of FOLFOX 
(Figure 4). As seen in the mentioned MIB-MS data from our lab, FOLFOX treatment led to increased 
expression of p-JNK, total JNK, p-c-Jun, and total c-Jun relative to the vehicle control.  
 
 
Figure 4. Phosphorylated JNK and c-Jun show increased expression levels 12 hours after FOLFOX 
treatment. *50 μM 5-Fluorouracil (5-FU) and 5 μM Oxaliplatin (OX) **100 μM 5-Fluorouracil (5-FU) and 10 










Total and p-c-Jun show a dose-dependent decrease in expression 12 hours after JNK-IN-8 treatment 
Cultured P0411 cells were treated with a DMSO vehicle as a control, or the JNK-IN-8 irreversible JNK 
inhibitor (Figure 5). A 1 M dose of JNK-IN-8 was selected based on the recommendation of the drug 
discoverers and 10 M was selected as a high dose9. JNK-IN-8 treatment led to a dose-dependent increase in p-
JNK, and a dose-dependent decrease in p-c-Jun and total c-Jun relative to the vehicle control. 
 
 
Figure 5. Total and p-c-Jun show a dose-dependent decrease in expression 12 hours after JNK-IN-8 









FOLFOX and JNK-IN-8 combination treatment led to a decrease in p-c-Jun expression 48 hours after 
treatment 
Based on the results seen in Figures 4 & 5, we then wanted to investigate the effect of a combination treatment 
of FOLFOX and JNK-IN-8 on the expression of p-c-Jun and total c-Jun (Figure 6). As seen in Figure 4, p-c-Jun 
and total c-Jun expression levels increase in response to FOLFOX. As seen in Figure 5, p-c-Jun expression 




Figure 6. FOLFOX and JNK-IN-8 combination treatment led to a decrease in p-c-Jun expression 48 











JNK-IN-8 treatment led to increased expression of tumor suppressors p53 and p21 after 48 hours 
To investigate the mechanism of downstream JNK pathway activation in response to FOLFOX treatment, the 
response of tumor suppressors p53 and p21 to JNK-IN-8 treatment was assessed. JNK-IN-8 treatment led to an 
increase in both p53 (Figure 7A) and p21 (Figure 7B). 
 
 
Figure 7. JNK-IN-8 treatment led to increased expression of tumor suppressors p53 and p21 after 48 













In vivo mouse study reproduced in vitro results 
To assess the reproducibility of the results seen in cultured cells in vivo, PDX tumors were grown in mice, 
biopsied by surgical incision, and then treated with JNK-N-8 by intraperitoneal injection twice weekly for one 
week. As in the in vitro results, all three tumors from mice treated with 30 mg/kg doses of JNK-IN-8 had 
increased expression of p-JNK, and decreased expression of p-c-Jun and total c-Jun relative to their pre-
treatment tumor biopsies (Figure 8A). One mouse was treated with a lower 15 mg/kg dose of JNK-IN-8 and 
also showed a large decrease in p-c-Jun and total c-Jun (Figure 8B). 
 
 
Figure 8. In vivo mouse study reproduced in vitro results. Three mice treated with 30 mg/kg doses of JNK-
IN-8 show an increase in p-JNK and a decrease in p-c-Jun and total c-Jun relative to expression levels before 
treatment (A). One mouse was treated with a lower, 15 mg/kg dose of JNK-IN-8, and also shows a large 
decrease in p-c-Jun and total c-Jun relative to expression levels before treatment (B). 
FOLFOX and JNK-IN-8 strongly synergize to inhibit PDX cell line growth at multiple constant-ratio dose 
combinations in 72-hour MTT assays 
An MTT assay was performed on cells treated with either FOLFOX, JNK-IN-8, or both (Figure 9A). Increasing 
doses predictably led to a decreased percent of viable cells relative to a control. The combination treatment of 
FOLFOX and JNK-IN-8 led to a lower percent of viable cells relative to a control than either in isolation. To 
assess whether the combination treatment synergistically decreased the percent of viable cells, combination 
indices were calculated using the publicly available Compusyn software14 (Figure 9B). At all doses evaluated, 
the FOLFOX and JNK-IN-8 combination treatment synergized. The combination treatment displayed the 
strongest synergy around the IC25 dose. 
 
 
Figure 9. FOLFOX and JNK-IN-8 strongly synergize to inhibit PDX cell line growth at multiple constant-
ratio dose combinations in 72-hour MTT assays. FOLFOX and JNK-IN-8 decrease the percent of viable cells 
relative to a control more than each in isolation (A). An assessment of synergy shows that the combination 







 Our results support our hypothesis that PDAC cells resist FOLFOX chemotherapy treatment in part by 
upregulating JNK, and that inhibiting this pathway could act synergistically with FOLFOX to treat PDAC.  
 When PDAC cells were treated with FOLFOX, the JNK pathway was activated as evidenced by 
increased expression of both phosphorylated and total JNK and c-Jun (Figure 4). The JNK pathway activation 
serves as a stress response and possible avenue of chemotherapy resistance for the PDAC cells. Previous studies 
have shown that cancer cells can mitigate the effects of chemotherapy and targeted inhibitors through kinome 
reprogramming8. JNK pathway activation in response to FOLFOX is kinome reprogramming that allows the 
PDAC cells to better proliferate under chemotherapy. 
 Since we observed JNK pathway activation as a stress response to FOLFOX treatment, we hypothesized 
that pre-emptively inhibiting the JNK pathway in combination with FOLFOX would decrease phosphorylated 
c-Jun expression and cell growth. 
 To inhibit the JNK pathway, the JNK-IN-8 inhibitor was obtained. JNK-IN-8 is a covalently binding, 
irreversible inhibitor that prevents phosphor-JNK from phosphorylating and activating c-Jun. The effect of 
JNK-IN-8 on PDAC cells was first investigated without simultaneous FOLFOX treatment (Figure 5). A dose-
dependent decrease in phosphorylated c-Jun and total c-Jun expression was observed. The dose-dependent 
decrease in phosphorylated c-Jun expression supports that, as Zhang et al.10 found, JNK-IN-8 prevents JNK 
from phosphorylating c-Jun. The decrease in total c-Jun expression, which indicates that more c-Jun was being 
degraded than translated, was not predicted. However, it has been previously shown that phosphorylation of c-
Jun by JNK leads to increased c-Jun stability13. A dose-dependent increase in phosphorylated JNK expression 
was also observed (Figure 5). This may be evidence of upstream pathway activation attempting to compensate 
for the downstream inhibition of c-Jun. However, experiments examining the response of JNK activators 
MKK4 and MKK7 to JNK-IN-8 treatment will need to be performed to support and explore these compensation 
mechanisms. 
 The combination treatment of FOLFOX and JNK-IN-8 was then investigated (Figure 6). Decreased 
expression of phosphorylated c-Jun was observed in the combination treatment in comparison to the control, 
and to an even greater extent in comparison to the PDAC cells treated with FOLFOX only. This shows that 
JNK-IN-8 successfully inhibits c-Jun phosphorylation, despite the upregulation of phosphorylated c-Jun when 
cells are treated with FOLFOX only. We find this to strongly support our hypothesis. 
 The in vivo mouse studies have thus far reproduced the results seen in vitro. As seen in vitro, JNK-IN-8 
treatment led to decreased expression of phosphorylated and total c-Jun, and an increase in phosphorylated JNK 
(Figure 8). One mouse treated with a lower 15 mg/kg dose of JNK-IN-8 also exhibited the decrease in 
phosphorylated and total c-Jun expression, indicating that this lower dose can be used in future mouse 
experiments. This is important because lower doses minimize toxicity to the organism. 
  The MTT assay also supports that JNK-IN-8 and FOLFOX in combination would be an effective 
treatment regimen. Synergy was observed when PDAC cells were treated with FOLFOX and JNK-IN-8 (Figure 
9). This is significant because any increase in dosage leads to higher toxicity. The strong synergy observed 
indicates that the combination treatment at a given toxicity would be more effective at treating PDAC than a 
corresponding dose of either FOLFOX or JNK-IN-8 yielding the same toxicity. 
 There is still much pre-clinical research to be done on the combination treatment of JNK-IN-8 and 
FOLFOX before the treatment can move into the clinic. All of the results presented here were presented from 
the same cell line. While we have seen some of the results replicated in the other cell lines we have used, we 
need to reproduce all of the experiments shown in a few other cell lines. Specifically, a high and a low baseline-
expressing c-Jun cell line from our cell line panel (Figure 3) should be chosen. Additionally, we want to further 
investigate the mechanism for how FOLFOX leads to JNK pathway activation. This will include an 
examination of other signaling molecules both upstream and downstream of JNK. Likewise, the signaling 
effects of JNK-IN-8 in isolation need to be further characterized. The observed increase in p53 and p21 
expression in PDAC cells treated with JNK-IN-8 (Figure 7) present early evidence that c-Jun inactivation leads 
to increased apoptosis, but this should be further investigated using other methods. Lastly, the in vivo mouse 
studies will be expanded to replicate all experiments performed in vitro. A synergistic decrease in mouse tumor 
size upon combination treatment with JNK-IN-8 and FOLFOX would present particularly strong evidence for 
the potential efficacy of this treatment in humans.  
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